Sight Sciences, Inc. (NASDAQ:SGHT) Insider Sells $17,121.28 in Stock

Sight Sciences, Inc. (NASDAQ:SGHT) insider Jeremy B. Hayden sold 4,864 shares of the company’s stock in a transaction that occurred on Friday, January 3rd. The shares were sold at an average price of $3.52, for a total value of $17,121.28. Following the transaction, the insider now directly owns 153,823 shares of the company’s stock, valued at $541,456.96. The trade was a 3.07 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Sight Sciences Stock Down 2.6 %

NASDAQ SGHT traded down $0.09 during trading hours on Monday, reaching $3.40. 235,749 shares of the company’s stock traded hands, compared to its average volume of 240,716. Sight Sciences, Inc. has a 52-week low of $3.30 and a 52-week high of $8.45. The company has a debt-to-equity ratio of 0.36, a current ratio of 10.18 and a quick ratio of 9.74. The firm has a 50-day simple moving average of $3.97 and a 200 day simple moving average of $5.60. The firm has a market cap of $172.57 million, a PE ratio of -3.33 and a beta of 2.57.

Sight Sciences (NASDAQ:SGHT) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.01. Sight Sciences had a negative return on equity of 47.28% and a negative net margin of 63.30%. The firm had revenue of $20.16 million for the quarter, compared to analysts’ expectations of $20.41 million. Sell-side analysts anticipate that Sight Sciences, Inc. will post -1.01 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts recently commented on SGHT shares. Citigroup decreased their target price on Sight Sciences from $5.80 to $4.60 and set a “neutral” rating for the company in a report on Wednesday, December 11th. Piper Sandler reaffirmed a “neutral” rating and issued a $5.50 target price (down from $6.00) on shares of Sight Sciences in a research report on Friday, November 8th. Needham & Company LLC reiterated a “hold” rating on shares of Sight Sciences in a research report on Friday, November 8th. Morgan Stanley decreased their price target on shares of Sight Sciences from $7.00 to $5.00 and set an “equal weight” rating for the company in a research note on Monday, November 11th. Finally, UBS Group started coverage on Sight Sciences in a report on Friday, December 6th. They set a “buy” rating and a $5.50 target price on the stock. Five research analysts have rated the stock with a hold rating and one has issued a buy rating to the company. According to MarketBeat, Sight Sciences has an average rating of “Hold” and an average price target of $5.12.

Hedge Funds Weigh In On Sight Sciences

Several institutional investors and hedge funds have recently modified their holdings of SGHT. SG Americas Securities LLC purchased a new stake in Sight Sciences during the 3rd quarter valued at about $75,000. The Manufacturers Life Insurance Company bought a new position in shares of Sight Sciences in the second quarter worth approximately $95,000. GSA Capital Partners LLP purchased a new stake in shares of Sight Sciences during the third quarter valued at approximately $136,000. American Century Companies Inc. increased its position in shares of Sight Sciences by 31.1% during the second quarter. American Century Companies Inc. now owns 35,948 shares of the company’s stock valued at $240,000 after acquiring an additional 8,527 shares in the last quarter. Finally, Rhumbline Advisers raised its holdings in Sight Sciences by 40.1% in the 2nd quarter. Rhumbline Advisers now owns 40,811 shares of the company’s stock worth $272,000 after acquiring an additional 11,671 shares during the last quarter. 55.51% of the stock is currently owned by institutional investors.

Sight Sciences Company Profile

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.